Furthermore, such a mechanism may be functional in the clinical setting as HRGβ1 is highly expressed in some EGFR-positive breast cancers, thus providing a possible de novo resistance mechanism to any utilized anti-EGFR therapy. The gene discussed is EGFR; the disease is breast cancer.